STOCK TITAN

Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Therapeutic Solutions International (TSOI) announced that its subsidiary, Campbell Neurosciences, achieved promising results in an animal model of schizophrenia using tolerogenic dendritic cells. These cells suppressed various neurological symptoms and increased T regulatory cell counts. Dr. James Veltmeyer emphasized the potential of immunology in treating neurological diseases. Campbell Neurosciences focuses on combating suicide through immunology and regenerative psychiatry, with a clinically validated blood test for suicidal ideation, the Campbell Score, and 13 patent applications covering diagnostics and therapies.

Positive
  • Successful animal study showing reduction of schizophrenia symptoms due to tolerogenic dendritic cells.
  • Increased T regulatory cell counts associated with therapeutic activity.
  • Campbell Neurosciences has a clinically validated blood test for predicting suicidal ideation.
  • 13 patent applications filed for novel diagnostics and therapeutic solutions.
Negative
  • None.

ELK CITY, Idaho, June 10, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today that its subsidiary, Campbell Neurosciences, recently obtained data demonstrating that the administration of tolerogenic dendritic cells in an animal model of schizophrenia resulted in suppression of multiple neurological manifestations of the condition.  Of great interest was the association between increased numbers of T regulatory cells and therapeutic activity. Previously the Company reported that administration of T regulatory cells are capable of suppressing schizophrenia.

"It is incredible to contemplate that immunological reactions such as the ability of tolerogenic dendritic cells to induce T regulatory cells can be used to treated neurological diseases.  The interplay between the brain and the immune system is the foundation of Campbell Neurosciences, and I am very excited to lead the translation of this very relevant animal study into human clinical trials," stated Dr. James Veltmeyer, Chief Medical Officer of the Company.

Campbell Neurosciences was originally founded as a division of Therapeutic Solutions International and subsequently spun off as an independent company, which is focused on ending suicide using immunology and regenerative psychiatry.  The company was founded by Kalina O'Connor, the President and CEO of the Company, whose mother, Kathleen O'Connor, and uncle, Hugh O'Connor (son of Carroll O'Connor), were victims of suicide.

"The only way to put an end to this silent epidemic of suicide is to aggressively approach it as a biological disease and not as a choice that people of weak minds make," said Ms. O'Connor.  "I have three young kids; suicide is the second largest cause of death in young people.  As a daughter of someone who was a victim of suicide, and as a mother now, I feel like not enough work is being done.  That is why I am extremely grateful to our investors, our collaborators, and our team that every day is advancing knowledge to the biological causes of suicide."

Campbell Neuroscience's lead product is the Campbell Score, a clinically validated blood test for prediction of suicidal ideation. Additionally, the Company (TSOI) has 13 patent applications filed covering diagnostics and therapeutic solutions.

"Schizophrenia is a very peculiar disease which possesses numerous immunological connections," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "There is much cross-fertilization that occurs between our two companies, especially from the sense that TSOI is focused on using the immune system to kill cancer, whereas Campbell is using the immune system to detect and to alter neuronal activities.  Through these interactions we continually develop new ideas, experiments, patents, and ways of interpreting preclinical and clinical data.  It is a real pleasure to collaborate with Campbell Neuroscience on this very important life issue."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

ir@tsoimail.com

 

Cision View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-spinoff-campbell-neurosciences-reports-reduction-of-schizophrenia-activity-in-mice-subsequent-to-administration-of-tolerogenic-dendritic-cells-301309916.html

SOURCE Therapeutic Solutions International

FAQ

What recent development did Therapeutic Solutions International (TSOI) announce?

TSOI announced that its subsidiary, Campbell Neurosciences, demonstrated that tolerogenic dendritic cells reduced schizophrenia symptoms in an animal model.

What is the Campbell Score developed by Campbell Neurosciences?

The Campbell Score is a clinically validated blood test designed to predict suicidal ideation.

How many patent applications has Therapeutic Solutions International filed?

Therapeutic Solutions International has filed 13 patent applications related to diagnostics and therapeutic solutions.

What potential does Dr. James Veltmeyer see in the recent findings?

Dr. Veltmeyer sees significant potential in using immunological reactions to treat neurological diseases.

THERAPEUTIC SLTNS INTL

OTC:TSOI

TSOI Rankings

TSOI Latest News

TSOI Stock Data

3.91M
3.78B
22.57%
Biotechnology
Healthcare
Link
United States of America
Elk City